HB Wealth Management LLC Buys Shares of 2,735 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

HB Wealth Management LLC acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 2,735 shares of the company’s stock, valued at approximately $373,000.

Several other institutional investors have also recently added to or reduced their stakes in NBIX. State Street Corp lifted its position in shares of Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after purchasing an additional 539,936 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 639.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after purchasing an additional 363,863 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Neurocrine Biosciences by 23.0% during the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after purchasing an additional 228,444 shares during the last quarter. Braidwell LP raised its stake in Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock valued at $105,734,000 after buying an additional 158,665 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Neurocrine Biosciences by 45.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 472,929 shares of the company’s stock worth $65,097,000 after buying an additional 147,907 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on NBIX. Royal Bank of Canada dropped their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Wedbush reiterated an “outperform” rating and issued a $148.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Raymond James restated an “outperform” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average price target of $164.81.

Neurocrine Biosciences Trading Up 0.6 %

NASDAQ NBIX opened at $147.58 on Friday. The business’s 50 day moving average is $132.97 and its two-hundred day moving average is $131.30. The stock has a market capitalization of $14.94 billion, a price-to-earnings ratio of 39.57 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98.

Insider Buying and Selling

In other Neurocrine Biosciences news, CEO Kyle Gano sold 65,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the sale, the chief executive officer now directly owns 135,392 shares in the company, valued at approximately $19,157,968. The trade was a 32.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the completion of the transaction, the insider now owns 2,507 shares of the company’s stock, valued at $338,445. This represents a 30.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,694 shares of company stock valued at $9,676,730 over the last quarter. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.